Status:
TERMINATED
Pharmacokinetics of Valacyclovir Oral Solution in Children
Lead Sponsor:
Radboud University Medical Center
Conditions:
Herpes Simplex Virus Infection
Varicella Zoster Virus Infection
Eligibility:
All Genders
2-12 years
Phase:
NA
Brief Summary
Valacyclovir has replaced acyclovir in many clinical scenarios. Pharmacokinetic data support the use of oral valacyclovir in children, but practical problems exist in children having to take adult-dos...
Eligibility Criteria
Inclusion
- Subject is in the age of 2-12 years.
- Subject has an indication for (val)acyclovir prophylaxis and are planned to receive valacyclovir oral solution.
- Subject is managed with a central venous catheter (CVC/Port-a-Cath).
- Subject's parents have signed the Informed Consent Form prior to screening evaluations.
- Subject is willing to participate after study procedures are explained in comprehensible language for the child.
Exclusion
- Severe anemia (\<6.0 mmol/L).
- Full dose has not been taken.
Key Trial Info
Start Date :
December 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 12 2021
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT04081480
Start Date
December 10 2019
End Date
May 12 2021
Last Update
June 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prinses Maxima Centrum voor kinderoncologie
Utrecht, Netherlands